Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

BICO, Capital Markets Day, 2024

By Inderes9/17/2024, 11:00 AM
BICO Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Jacob Thordenberg
00:00 - 00:42

Everyone, a warm welcome to BICO's Capital Markets Day. I would like to welcome everyone to BICO's head office in Gothenburg, as well as all of you joining us online. My name is Jacob Thordenberg and I'm the CFO of BICO AB since January 2023, but joined the company in December 2021 as head of M&A. And during this period, BICO acquired A0 and Allegro 3D. With that brief introduction, I will now hand it over to my colleague Anders Fogelberg, who joined us in June this year. He's become Chief Commercial Officer and will be the moderator of this event. Thank you, Jacob. And again, welcome everyone.

Anders Fogelberg
00:42 - 02:11

This is an exciting day. We will have a quite a full program in the next few hours, including this online seminar, the Online Capital Markets Day, and more. This session will be divided into three main sections. We will start by presenting the BICO update strategy, BICO 2.0, and also present on new business areas and comment on our financial targets. This will be followed by a deep dive into lab automation, and this will be presented by our operating company Biosero and their customer, DeepCure, who has come here from San Diego. We have an issue with the screen that is not working, and the technical team is working on it right now. But I'll go ahead and continue with presenting the third part of the day, which will be the Q&A at the end of this Capital Markets Day and during the Q&A. Those of you who are online can click on the chat box below the presentation and ask questions now and throughout the event. And those of you who are here in Gothenburg, you can raise your hand and you will be able to participate live, of course. I think we just saw a disclaimer, and we also see now the program for today that I just presented. And with those words, I welcome you. I present to you the president and CEO of Baker, Maria Forss.

Maria Forss
02:12 - 39:37

Thank you, Andres. Thank you for the introduction. And also a warm welcome to all of you. Also, for me, this day is an important milestone for the Baker Group, and it's also a day that I've been looking forward to for quite some time. And for those of you who I haven't had the opportunity to meet yet. I'm Maria Forss and I'm the CEO and president of BICO AB since November 2023. Our purpose with this Capital Markets Day is to present an updated strategy for BICO 2.0, where our new vision is to enable and automate the life science lab of the future. We will do this with a mission to be the first choice lab automation partner and provider of selected workflows for pharma and biotech. Before I provide more details on how we will get there, I will provide some context and also some background about BICO, the market we're operating in, and also the trends that we see. BICO has a global presence in 65 markets around the globe where North America is the most important market, followed by Europe. The group has around 820 employees working for our 12 companies, and full year sales in 2023 amounted to 2.2 billion Swedish kronor. We have more than 46,000 instruments installed around the world, and this has generated more than 12,000 publications. Jacob Thordenberg will later present more financial numbers in the presentation following this. For a company founded in 2016. This has been a tremendous journey through both organic growth as well as acquisitions, the majority of which were made at a rapid pace. During the pandemic years, acquisitions totaling about 7 billion Swedish kronor were made, which has provided us with a broad and differentiated product portfolio. This was done at a time when interest rates were low and acquisition multiples were high. There was a Covid boom, and the full focus was on growth. As for many players in the market, when the macro world changed, the focus instead had to be on profitable growth, and the development in some of the acquired companies didn't go as forecasted, and hence writedowns had to be made, which were technical in nature. Post-Covid, there has been a downturn in R&D. There have been CapEx restraints. Biotech has been having a tough time with financing, and academia's budgets have been negatively impacted by the development of the stock market over the past 18 months; during this period, the organization has been on a transformation journey, rightsizing the organization and better utilizing the organizational synergies that a larger group entails. And a part of this journey had already started when I joined the company in November last year, and we managed to perform rather well, despite the recurring restructuring and internal changes in a quite tough market; we have performed in line with, or even better than, some of our peers in an unpredictable market, and this is partly due to our very passionate and dedicated colleagues around the world. Making a difference is a strong desire for the entire team. We know that our solutions are an integral part of research that leads to important medical innovations, and they make a difference in the lives of people. Earlier this year, we launched four strategic focus areas to drive commercial excellence through a complete strategic review. Invest in people and culture and also continue the operation. Ericsson's initiatives that were started back in 2023. We have since worked diligently within these prioritized areas, and I will now present some examples of the achievements that we have made. Sales per employee increased by 12%. If you compare quarter two, 2024, with quarter two, 2023. In driving commercial excellence, our new Chief Commercial Officer, Anders Fogelberg, has established a cross-company sales skills team to further reap sales synergies. We have also established a communication skills team to coordinate marketing efforts across the group. As the key Congress SLAs in February in Boston this year, you saw on the previous slide that we had Congress attendance for the first time under a joint BICO flag, to name a few examples of things that we have done. Customer centricity and customer care are essential in our entire value chain and guide our focus in R&D as well as in marketing. We have also generated more customer insight data during the year as part of a strategic review. We have conducted a comprehensive review of all R&D projects as well as the entire group portfolio, and of course, extensive strategic work involving all the different operational companies within the group. And we're not yet fully ready with the portfolio optimization. Our Chief HR Officer, Katharina Newland. She has implemented a global HR organization and an HR strategy, embodying the principle that 'Culture Eats Strategy for Lunch.' We have also worked a lot to form a joint culture, and we recently launched our new corporate values internally for all employees. And these are trust, focus, collaboration, and grit. We have also continued with operational excellence improvements, such as targeted cost reduction programs. For the past five quarters, we have improved our working capital from a level of 33% and now deliver a range of 20 to 24% in net working capital for LTM. And this has, for instance, been driven by an inventory reduction of 130 million year over year, as well as better management of accounts receivable through consolidating global category management and volume bundling. Together with our strategic suppliers, we have also achieved quite substantial cost savings. Other projects include facility consolidation as well as logistics optimization, which have also generated savings that better govern our R&D. And through other key initiatives in the group, we have also put a global project management PMO in place. So these are some examples of all the endeavors that we have done throughout the year. With all of this, BICO has now a much better foundation and position than ever to capitalize on the current trends with technologies that support the market shifts. We're doing all the right things. He thinks we're on a good path to create a stronger company for the next step, but there is still a lot to do, and there's still a downturn in the market for R&D. With our updated strategy 2.0, we are leaving one phase behind, and with new executive management in place, we are now entering a new phase. And it's my pleasure to present to you the BICO executive management, our CFO, Jacob Thordenberg, whom many of you know since the beginning of last year. Jacob has around 15 years of experience in finance and M&A, both at BICO, Telia, and Deloitte. Our Chief Operating Officer, Marius Bulgar, with over 30 years in general business management, including 20 years in the life science and IVD industry leading a mid-sized CDMO, and being the senior vice president of the partnering business at Taicang, is one of the latest additions that has significantly strengthened our executive team. Our Chief Commercial Officer, Anders Fogelberg, having over 25 years of global industry experience from management positions such as Managing Director of SKF in Malaysia and Indonesia, as well as being CEO for a medtech company and, most recently, head of sales for a startup company in the life science industry. Katharina Nordland, our Chief Human Officer, has over 25 years of experience in HR and learning and development, as well as sales and marketing in global medtech and life science industries such as Cochlear, Monolithic Healthcare, Pfizer, and Surgical Science. In mid-October, our team will be complete for our current mission when our new general counsel, Andreas, joins us. He has over 15 years of experience working in an international business setting, including roles in law firms and most recently in an M&A-intensive environment, where he focused on establishing and building a legal team, and extensively worked on post-acquisition governance and integration. Thank you, Tim. And before I share more about the BICO journey, a few words on my route to BICO. And since I joined in November, this is one of the questions I'm most frequently asked about. I've spent over 25 years working in the pharma and life science industries, and during these years in global roles, I have successfully contributed to the entire value chain, in all segments of the product lifecycle from early development to launch and relaunch, across listed startups, mid-sized companies, and major pharmaceuticals like AstraZeneca. I've also worked with mergers and acquisitions from both the buyer and selling sides, integrating companies for successful commercialization of R&D projects. For the past 11 years, I've embarked on the same journey that BICO is now undertaking at the Swedish listed medtech company, which thrives. I'm now using my vast experience of running a complex business to ensure that we will leverage and commercialize the great assets and portfolio that Bako has. And I will now shed some light on how the BICO organization has been shaped, and how our products and services fit together to meet our customer needs. So if we take a step back, the BICO journey began in the field of bioprinting. The company set out on a course to democratize the upcoming field with accessible systems, high-margin reagents, and consumables. We open up an entire industry by enabling anyone to buy or print human tissues in the lab. The success in bioprinting catalyzed our first expansion, which focused on establishing an end-to-end solution, also catering to the pre and post-printing activities. Through engaging with customers in the bioprinting sector, we have gained insight into their workflows and needs. Pike embarked on an acquisition journey to provide them with the tools that they need. We did this by bringing on technologies relevant for both pre and post printing, along with complementary technologies like liquid handlers, microscopes, and lab automation software, where the latter makes this offering quite unique from a perspective. And this also opened the doors toward other spaces like next-generation sequencing and synthetic biology, expanding BICO's reach significantly. We have fantastic assets in BICO AB, and that makes some of the larger players in the industry envious. And these are assets that made me want to join because I wanted to be part of and lead a journey. When BICO takes the next steps in better commercializing our assets, scaling up our business. A journey we brought together with my experienced management team and all other engaged colleagues can make an impact in the life science industry. BICO has a broad footprint with a diverse portfolio and extensive geographical presence. We have a market-leading position with our hardware-agnostic lab orchestrating solutions as well as in bioprinting. We also have unique offerings that you will be able to see later today in automated shaking, heating and cooling, and also single-cell dispensing and cell line development. With this portfolio, we can serve customers in many different segments of the market, and we have a strong customer base in top pharma, biotech, diagnostics, as well as academia and research. Let's move into the next section of my presentation, where I will do my best to present the sometimes complex market that BICO is operating in. So within the larger life science landscape, BICO is operating in the field of biotechnology. The life science landscape encompasses a variety of scientific fields, and biotechnology is facilitating these adjacent fields through tools and services. The life science value chain encompasses four key areas, ranging from basic research to clinical applications. And because we are focusing our efforts within the pre-clinical domains, serving many different customer segments, we are offering solutions predominantly in molecular biology, drug discovery, and synthetic biology. And these fields contain distinct applications and workflows where BICO's portfolio of solutions is playing a role to a different extent. If we start with molecular biology, basic research and diagnostic testing are examples of applications in the field of molecular biology. In basic research, next generation sequencing is applied, and in this workflow, products from the Span-DEX Santana instruments and Biosero are being used in target discovery. Heat generation, lead identification, and target identification are examples of applications in drug discovery. This is done to uncover new medications, where products from more or less all BICO companies are being used in target identification and assay development. Synthetic biology is merging biology and engineering. This means biologics, proteins, and small molecules manufacturing for gene assembly with products from Spandex and Biosero being used for cell line development. Also, products from Cyanogen and Selenium come into play. Let us now look at the customer needs in the fields that BICO is serving in molecular biology, with high precision tools and automation. There are needs for integration of gene editing tools and automated systems for higher efficiency and throughput. And this is evolving to meet future needs with advanced AI integration for predictive modeling and gene editing technologies tailored to enable personalized medicine and drug discovery, where they work with high throughput screening and biomarkers. There are needs for technologies, also AI-enabled, for rapid compound screening and hit-to-lead generation, as well as for the detection of new biomarkers to advance personalized therapeutics and multi-omics. In the field of synthetic biology, there is a need for regulatory compliant platforms for genome synthesis and microbial engineering to produce high-value compounds and for advanced biofabrication and computational tools. There is also a need for biologically secured and sustainable solutions to enable biofabrication of complex structures. Through the current offering, BICO cooperates in a market totaling at 121 billion USD, growing at 12% annually, with a serviceable addressable market of 3 billion USD, averaging at the same CAGR as the overall market. And if we take a deeper look at the lab automation market, where integrated lab automation solutions are enabled through Biosero and more companies in the BICO group, the lab automation industry is currently evolving significantly, and there's a lot of market data reports circulating. As always, with an emerging industry, the data varies. So the lab automation market size was valued around 5.5 to 6.8 billion USD in 2023, with the growth rate indicated between 6.3% and 9.3% CAGR between 2023 and 2035, and the value for the integrated automated solutions, which BICO reserves, is estimated to be 20% of the total market, or around 1 billion USD. This segment of the lab automation market is growing and is expected to continue growing faster than the overall market within automated solutions. We offer hardware-agnostic software solutions key to the integration of automation technologies, plus consulting and engineering services to design, build, and install automated laboratory systems at any scale. If we move on and take a look. At the total addressable market for the different product segments, you can see that there's double-digit growth in all areas, and consumables hold a large share of 44%. And this is expected to grow 12% year over year, and is therefore deemed to be an attractive segment for BICO to pursue. Currently, two thirds of the current turnover in BICO is instruments, while one third is consumables, service, and software. For other companies in the industry. This is not uncommon; that this split is the reverse, which normally makes it easier to generate recurring revenues. Recurring revenues can be generated from all different revenue streams. Examples of opportunities for us include increasing software sales, linking consumables to workflows, selling more high-service, high-value service contracts, and also creating more standard operating procedures containing both instruments as well as consumables. And one example of that is our G Prep from Bendix. We can also increase recurring revenue from pharma and biotech customers. Pharma and biotech customers have a higher ability to spend, and they also demand solutions that meet more stringent regulatory requirements. And it's important to remember, though, that although the pharma and biotech business is not cyclical, their R&D spending is. Supporting life science customers in the early phases of the value chain. Because we aspire to address this in a more holistic way through end-to-end workflows. Pharma, biotech, and diagnostic companies are our strategic customers, and the ambition for Baco is to increase the share of our revenue from these customer segments. To conclude this section, I would like to summarize the key trends of importance for BICO AB. I believe that they highlight the opportunities that we see in the market, and we are in a good position to capture potential growth. There is a growing demand for integrated and automated workflows in labs for higher efficiency and throughput, as well as a need for advanced data and AI integration. As I noted earlier, there is also a need for technologies for rapid compound screening and hit-to-lead generation, along with an increased focus on personalized medicine and regenerative medicine. And we also see a demand for more regulatory compliant platforms. Last but not least, there is a growing adoption of in vitro testing instead of animal testing. And this is driven by, for instance, the FDA Modernization Act and other European counterparts, as the FDA Modernization Act 3.0 requires the Food and Drug Administration (FDA) to establish a process supporting non-clinical testing methods for drug development that do not involve the use of animals. So, combining our knowledge about the market, where our strengths and competitive advantages lie with the product offerings that we have. That is the basis for our choice of strategic direction. And this is why my next section will be all about our updated strategy and what our focus will be moving forward. Our vision is to enable and automate the life science lab of the future, and we aim to be the first choice lab automation partner and provider of selected workflows to pharma and biotech. We will continue with our strategic priorities and within this focus on certain areas within the domain of commercial excellence, we have identified five new focus areas. The first one is to enable lab-to-lab automation and further develop integrated data, AI, and software solutions. Thirdly, ensuring regulatory compliance readiness to even better serve biotechnology and pharmaceutical customers. And also moving away from point solutions to providing scientific workflow solutions in selected workflows and increased recurring revenue. A complete strategic review. Moving forward will encompass a more customer-centric R&D, a late-stage process for product development, and continual assessment of the strategic fit across our portfolio of assets, considering options that are positive for shareholder value. Investing in people and culture moving forward. This means fostering a culture of strong leadership by implementing a leadership development program. We will plan, attract, and retain talent to ensure that we can execute this strategy. We will harmonize, engage, and reward. For example, we will harmonize role levels, job architecture, and global compensation policies to ensure collaboration between our companies. And we will also deliver global HR operational excellence with support from global Performance Management as well as a global HR system within the area of operational excellence improvements. We also have several key initiatives moving forward, and to mention a few important ones. We will establish a global sourcing organization. We will roll out a strategic contract development and manufacturing organization partnership model. We will also implement a global QA organization. Furthermore, we continued to streamline and reduce costs in logistics, and also continue to focus on inventory reduction as well as footprint reduction for our facilities. So all in all, the lab automation and selected workflows are the cornerstones of our business offerings, and this is implemented through key processes and acts as the main enabler of group synergies. Bioprinting holds a differentiating position in BICO's portfolio, creating opportunities for the lab of the future, and these offerings are then enabled by a range of products and services. Instruments are provided as standalone products or paired with other offerings. Consumables are tactically positioned to augment the offering and provide relevant end-to-end solutions to achieve recurring revenue streams. Last but not least, that offering keeps BICO relevant also after the hardware purchases. Let me share some more details on the offerings that we have to drive. Commercial excellence. The holistic workflows. They are approached using three levels of integration: customized automation, off-the-shelf work cells, and standard operating procedures. Starting with the customized automation, these are product-based, highly customer-adapted. They are built on a standardized library of integrations, but also contain customer proprietary solutions. Normally, these are not reproduced in their entirety. Off the shelf work cells. These are whole or larger segments of scientific workflows that are contained within a single automated work cell. And one example of such is the C station from our company, cited for use in cell line development, and these work cells are developed and maintained at BICO as a part of our offering, featuring standardized configurations built around predefined article numbers, allowing for off-the-shelf manufacturing. Standard operating procedures are maintained by code, and are centered around BICO's instruments and consumables. They can also entail third party partnerships and licensing to generate a holistic offering, and here, several variations can be maintained for more specific applications. Let us now look into the customized automation solutions a bit deeper. As BICO looks to support the world's largest pharmaceutical companies and other scientists around the globe, a major theme is bringing new drugs and marketable discoveries to the market, which is a resource-intensive process. It takes years and sometimes even decades to develop these solutions, and it costs millions and even billions of dollars just to find the right compounds and prove that they deliver benefits. And this really brings us to the new major focus area for BICO, which is that we bring capabilities to accelerate scientific research through automation. We take what is challenging, slow, expensive, and traditional in scientific research and testing, and allow significant leaps in productivity and overall testing timelines to help you understand what I mean. I will walk you through the breadth of solutions that are at work in today's lab. It starts with manual work done by human hands to pipette liquid and process samples by hand. And there's power in digitizing the standard operating procedures to keep teams operating consistently. These days, scientists are more frequently supported by various forms of automation, where devices are introduced to perform specific tasks and steps. Devices often help with reproducibility and accuracy in science, thus ensuring that not just unique individuals are creating unique results. A survey published in Nature some years back revealed that 70% (seventy percent) had failed to reproduce other researchers' experiments, and over half of the researchers couldn't reproduce their own. And that highlights how reproducibility can be a challenge for scientists. Connecting these devices with industrial robotics and collaborative arms helps to take the burden off of these people in the lab even more, allowing scientists to focus on what they should be focusing on: being creative and doing data analysis while the robots keep the testing moving. Scientists take this type of device connectivity and robotics to the next level by automating significant proportions of their workflow. And finally, we reach the level of integrated laboratories, which is what we often implement for the largest labs around the world. Developing systems that can take in samples, process an entire scientific workflow in an automated fashion, connect to analysis software, and ultimately keep iterating on the science within the entire design, make, test, and analyze cycle. And because our portfolio includes many devices that are used across the spectrum, the key company to present to you is Biosero, which consults for labs in need of support along this entire spectrum. Biosero consults with the laboratory, taking into consideration their workflow, budget, and needs to develop a purpose-built, automated solution to accelerate the science within that particular lab. And the way we achieve this for labs is also driven by our software suite, which is deployed to each solution that Biosero deploys by series. Green Button Go software suite connects devices made by BICO and also other major manufacturers to allow digitization of manual processes up to full laboratory integration. At the highest level, this software is at the forefront of automation solutions because it's not just about a lab using one great device; it's about taking many great devices and weaving them into a robotic choreography that can operate 24/7 on a schedule. This type of integrated automation helps laboratories to cut their costs while increasing productivity, and it also helps to maintain high quality. One of our customers will buy from Biosero, and their lab automation solution is a big pharma company, and we are grateful to them for allowing us to share this data from their implementation of our solutions in one of their US R&D sites throughout the nation. Strategy enabled by Green Button Go from Biosero. This pharma company is reducing downstream processes and assay development by up to 75%, and this is due to increased equipment runtime. They're also increasing existing equipment capacity to develop biopharmaceutical manufacturing processes by up to 400%, due to parallel processing and variable-driven robotic processes. Also, they are maximizing the productivity of development scientists and labs by a minimum of 200%. Let me now show an example of how other products from Biosero's portfolio work together in an automated workflow, also utilizing Green Button Go. And this film is mainly for the benefit of those who are joining online. And for those of you who are present, because you will be able to see this physically later today. So to summarize, we lead the wave in solving the challenges in the life sciences with speed, accuracy, and efficiency. All in all, our customers can run their processes faster, improve the quality of the data, and ultimately make better decisions. Speed and accuracy combine to reduce the time needed to find optimal candidates for treatment therapies. We support our customers in driving forward a personalized approach in treatments. In addition, it is worth mentioning that we're also contributing to decreasing the use of animals for preclinical testing and improving efficiency as we develop solutions to maximize the productivity of both automated lab equipment and scientists. To encapsulate our vision and strategy on a page, our new vision is to enable and automate the Life Science Lab of the future. With a mission to be the first lab automation partner and provider of selected workflows to pharma and biotech. And we do this through commercial excellence with five new focus areas, enabling end-to-end lab automation solutions and further developing integrated data, AI, and software solutions. We ensure that we provide regulatory compliance and have the readiness to further support our customers in pharma and biotech. We move on through providing scientific workflow solutions rather than point solutions, and also increase our recurring revenues. We do this through our joint corporate values, the first one being trust, which is the foundation for everything. The next one being focus. We need to choose what to do, but also what not to do, and to reap success. We also need to collaborate both internally and externally. And last but not least, we need to do it with grit. And the impact that we will see from this is that our customers will experience increased speed and quality through automated technologies. They will have better efficiency in drug development, and we are also providing tools to accelerate personalized medicine and alternatives to animal testing. So Anders, I hand over to you.

Anders Fogelberg
39:39 - 40:34

Thank you, Maria, for updating us with the BASIC 2.0 strategy. Next, we will look into how this strategy impacts our organization and how we organize ourselves into business areas. We will look at our financial targets. But first, we will have a 15-minute break and we will be back here in 15 minutes sharp. Welcome back. We spent the first part of the Capital Markets Day today presenting the big updated strategy that we call Breakout 2.0. We will now look into what that means for our organization, our business areas, and we will also comment on our financial targets. And this session will be presented by our CFO, Yakov Dunbar, and supported as well by our president and CEO, Marius Jacob.

Jacob Thordenberg
40:38 - 48:20

Thank you, Anders. This session will be split into two broad parts: new business areas and comments on financial targets. On this slide, you see the business area structure, which we have reported on since Q1 2022, which has been based on three business areas: bioprinting, bioscience, and bioautomation. To better reflect the updated strategy and our commercial focus, we have decided to introduce new business areas. As you can see on this slide, a new business area structure has taken shape. As Maria mentioned earlier, our strategy is centered on lab automation being one of our key pillars, and we have therefore decided to introduce lab automation as a new business area, which will include our Bio Zero, our market-leading company within integrated lab automation. In addition to lab automation being a cornerstone in our strategy, this will also increase the transparency of our financial profile, as Bio Zero has a different business model and financial profile compared to our instrument companies due to its project and software business. Primarily, this relates to Biosero having a percentage of completion revenue. Recurring revenue recognition model, which creates significant revenues when a project is started and when instruments for the projects are typically acquired. An example of this was the Q1 2024 growth spike in biosciences, when some of the revenues related to the $28 million order by A01 in December 2023 were recognized. Furthermore, Biosero also has a lower gross margin profile than our instrument companies due to the significant share of third-party hardware included in COGS, resulting in a lower gross margin than the instrument companies, but still a healthy absolute gross profit in relation to OPEX and thereby also EBIT margin. Additionally, we will also introduce Life Science Solutions as a new business area where we will offer instrument-selected workflows and complementary offerings. This business area will consist of the SpanDEX instruments Sci, Onion, Selenium, and Echo. Our third business area, bioprinting, will be kept intact and will continue to include operating companies selling advanced biometrics, medtech, vesicle, and NanoScribe. We will begin to report in our new business area structure from Q3 2024. And because of this change, we will postpone our Q3 report by two weeks until November 26th. On this slide, we are presenting our service's addressable market by business areas. As already mentioned by Maria, the average expected growth rate is around 12%, with the largest addressable markets in lab automation and Live Science solutions, followed by bioprinting for increased visibility. I will add this slideshow of the full year 2023 revenues, showing the transition from the old structure with bioprinting, bioscience, and bio automation to the new structure with lab automation, Live Science Solutions, and bioprinting. Live Science Solutions will be the largest business area, followed by bioprinting and lab automation. On this slide, we have collected two key metrics: sales and adjusted EBITDA for the full years 2022 and 2023, and the first six months of 2024, with the old business areas on top of the slide, followed by the new business areas underneath. Please note that when looking at the first six months of 2024, this is our and the industry's seasonally weakest part of the year, followed by typically a seasonally stronger second half of the year due to budget releases at the end of the year. And because this seasonal pattern mainly applies to business areas like Live Science Solutions and bioprinting. Furthermore, group costs are not included in adjusted EBITDA per business area, as this is reported separately in our reports. Starting with stats, lab automation has developed strongly during this period and recorded almost a 40% sales increase from 2022 to 2023 due to the strong underlying market growth. In combination with our market leading software and company in lab automation, Biosero. The major driver behind this growth is that the lab industry took a giant technical leap forward in connection to Covid, due to the sharp increase in demand for faster and more efficient drug development, which triggered a new, much more modern and digitalized way of conducting research using automated labs. As Maria mentioned earlier, the market is expected to have continued growth for the years to come, as this modernization journey for many companies, including Big Pharma, is still in its early phase. Live Science solutions, which include our instrument companies, have managed to maintain sales levels fairly well during this period in a tough market that is still recovering from a post-pandemic slump following the Covid boom and general CapEx expanding spending restraints in the industry. These general spending constraints have clearly been tough for Live Science solutions, but for BICO, this development has been offset by our offerings in lab automation being the answer on how to reduce costs and be more efficient. And as previously communicated, bioprinting has had a negative trend for the past quarters, primarily related to weak demand from a soft market in Asia, as well as academia and research in general, with sales being mostly impacted. And if we want to adapt to better lab automation, it has delivered good margins, which have improved over the years. And for the first half of 2024, following the strong sales growth between 2023 and 2022, Live Science Solutions showed a significant improvement in profitability between 2022 and 2023, mainly due to the major cost-saving programs launched in 2022. But it has had a tough start to 2024 from a profitability perspective, mainly explained by the tough market, especially in the diagnostics segment, which BICO is addressing. As for development in bioprinting, this is, as mentioned, related to weak demand from research and academia, with Cellec being the most impacted. To address this, we have a new management team in place and have launched both commercial and cost-saving measures to improve profitability. I will now let Maria present how the new business area structure affects areas of responsibility in the executive management.

Maria Forss
48:23 - 50:00

Thank you. And as Jacob stated, the new business area structures also affect some areas of responsibility, especially in the executive management. I will, apart from my current responsibilities, also take on the role as responsible for the business area of lab automation and, as Chief Commercial Officer, will lead the business areas of Life Science Solutions and bioprinting. Jacob Thordenberg, our CFO, will continue to be responsible for the finance function, which entails business control and corporate development, group accounting and internal control, business process solutions, IT, Treasury, and investor relations. Moving on to operations. This will continue to be the responsibility of our Chief Operating Officer, Marius Bulgar. He will be responsible for the operations organization, project management, office quality assurance, and regulatory affairs, as well as the portfolio of project management. Andreas, who will join us in mid-October as our new General Counsel, will be responsible for corporate governance and compliance. In Katarina, Nordland, our chief HR officer. Her area of responsibility includes the global HR organization as well as internal communications. All in all, a solid structure for our updated strategy and I will now hand over back to your group for presenting our financial targets.

Jacob Thordenberg
50:05 - 53:59

Thank you, Maria. And if we move on to the next slide. As many of you know, we introduced our current financial targets during the Capital Markets Day held in November 2022. And they have been valid since 2023 and communicated to be achieved on a mid-term basis, defined as within three years. The three financial targets consist of metrics related to organic growth, EBITDA, and net debt. On this slide, you can see how BICO AB has performed so far. We can conclude that we are still behind and have not yet achieved our growth target. This can be explained by 2023 and so far also 2024 being tough years for many companies in the lab instrument industry operating in the same market. We are also experiencing the same trends and patterns. However, it is worth mentioning that Beko has delivered in line with peers. Even though we are going through a tough restructuring and cost-saving phase. With that said, we have not yet achieved the target. As for the profitability target, we have seen a positive trend in the right direction, but we have not yet achieved the target. The net debt target has so far in 2024 not been achieved, but was achieved in 2023. While looking at the financial targets and considering the tough market we are operating in, still suffering from a post-pandemic slump following the Covid boom and with spending and CapEx restraints, we believe we are taking steps in the right direction and are confident that the updated strategy long term will support us in achieving our targets. And we have therefore decided to reiterate our current financial targets. The rationale behind this decision is that we believe the targets are still relevant, and we want to deliver on the existing targets before setting new ones, which we intend to define when the current targets have been achieved. Meeting the already set targets will continue to be our top priority, and I will therefore repeat and comment on the reiterated targets. As for the growth target, the low double-digit organic growth captures and shows market growth opportunities in line with our assessment of the market. As previously communicated by both Maria and myself, the above 10% EBITDA margin, less capitalized or indeed targeted, secures our focus on profitability, including total R&D spend, and enables positive cash flows. The net debt target in relation to EBITDA of less than three times is the target we believe is suitable for a company with our profile. When discussing the financial targets, including the net debt target, I will also comment on the convertible bond and refinancing. The bond is due in March 2026 and has an interest rate of 2.75 percentage points and no material covenants. Hence, the terms for the convertible bond are attractive for BICO and the existing solution serves as well. However, although the bond doesn't mature until March 2026, refinancing of the bond is an important project that we are actively working on and we are evaluating various options, including the strategic fit of our portfolio of assets, to ensure that we are maximizing shareholder value and acting proactively. This was my last slide, so I will now hand it back to Anish.

Anders Fogelberg
54:03 - 54:43

Thank you, Jacob and Maria. We have now presented the BICO update strategy and business area and reiterated our financial targets. We will now change the subject and have a deep dive into lab automation. In addition to that, we will also look at how AI coupled with lab automation creates additional customer value. And I'm happy to have with us the CEO of Biosero. Ryan Bernhardt from San Diego in California. And with him we have Derrick Miyao. He is VP of Molecular Foundry at the US company DeepCure. And both of them will present. And we will start with Ryan.

Ryan Bernhardt
54:47 - 69:36

Thank you very much, Anders. And hello, everyone. It's a pleasure to be here today, and I'm excited to have the opportunity to tell you a little more about lab automation and Biosero. And I'm honored to be joined by Derrick Miyao, who will take you through his journey of partnering with Biosero to implement automation that's been transformative to his business. As Maria touched upon earlier, one of the biggest challenges that the life sciences industry faces is the reality that discovering drugs, cures, therapies, and diagnostics takes longer and costs more than it should. Do you know how long or how much it costs to get a drug to the market today? On average, it takes nearly 12 years and $2.3 billion to get a drug to market. The life science industry is looking at ways to overcome this, aiming to cut this in half. And there are many initiatives, known as Pharma 4.0, next-generation research, and next-generation development. But the reality is that the drug discovery process has historically been largely built around manual capabilities and processes. And with this comes a great deal of variability, not only in technique but also in timing. And this is where Biosero and lab automation enter the scene. So why do labs automate and why have labs not automated in the past? We automate because it starts by exploring a better way to do science. With automation, we have the ability to increase the reproducibility of scientific results. As Maria touched upon earlier, one of the most difficult things to do in science is to have another lab that's able to reproduce the scientific results of another lab. In addition to that, it's also hard for a scientist to reproduce their own experiments in the same lab. So with this, automation not only enables reproducibility by embedding the technique and the processes into the automation, but it also enhances the quality of the science that's being performed and also enhances the quality of the data that's being generated. As timestamps are taken. Time stamps are taken when actions occur, allowing us to capture that data in real time, not just some of the data, but all of the data. In addition to that, automation increases the productivity of laboratories. Robots don't need a lunch break. They don't call in sick, they don't get tired, and they don't leave the lab at 5 p.m. to go home for the evening. This means that automation can continue to be productive around the clock, utilizing the same finite amount of time in a day, a week, and a year to accelerate project timelines. In addition, lab automation also increases the efficiency of scientists within the laboratory while it runs scientific experiments and assays. A scientist is then freed up to focus on higher-level tasks, where they tap into the power of the human mind by being able to analyze data, design experiments, and focus on collaboration. And in addition to this, automation also increases the safety of science within the laboratory. We saw this firsthand during the Covid pandemic, where automation was used to handle infectious samples, thereby keeping scientists safe. In addition to safety, automation also minimizes ergonomic risks and strain by allowing scientists, who would otherwise have to perform repetitive tasks over and over again, to benefit from automation. And finally, automation also enables additional sustainability within the laboratory, where automation can monitor progress and keep track of what's happening. But it can also miniaturize the experimentation and the volumes of reagents, compounds, and solvents that are being used, all while minimizing the amount of waste generated during the scientific experimentation. So based upon these benefits, you may ask yourself, well, why have laboratories to date not implemented automation? And although the laboratory is a place of innovation. Historically, the laboratory has been a place of conservative traditional practices and it takes a lot of energy, effort, time, and even cost to overcome some of those traditional practices due to regulatory regulations within the laboratory. And while this was true, all of a sudden in 2020, the COVID-19 pandemic occurred. And those traditional practices and techniques were all of a sudden challenged and overwhelmed by the reality of what was happening during the pandemic, labs that were used to processing 15,000 samples a year were now being asked to process 15,000 samples a day in order to perform Covid testing. Those scientists that were readily available in the lab. Now, we were not available in the lab due to social distancing and a decrease in productivity. Still, productivity had to continue even while people were at home. And so we needed a way to monitor what was happening inside the lab. And with this, the processes were overwhelmed to the point where there was no choice but to begin leveraging automation for the task. And once automation was implemented, the benefits were such that laboratories did not look back or revert to traditional methods. And it catapulted the industry by over a decade and necessitated organizational change management. And so in a post-pandemic world, the trends in lab automation today are that lab automation is needed closer to the patient and closer to the end product than it was a couple of decades ago. Lab automation was primarily seen in early phase discovery research, where it was used for compound management and high throughput screening, making it very tough to calculate a return on investment. Today, with the rise of new modalities such as cell and gene therapy, liquid biopsy, and next-generation sequencing, automation is needed closer to the patient, which means it's also needed in regulated environments. In addition to that, labs are more open to leveraging off-the-shelf automation solutions today than ever before because of the pressures on their internal businesses. You see, the pharmaceutical industries' main goal is to get medicines to the market that will impact patients, not to develop scheduling software or custom robotic systems. So, these organizations are now open to leveraging businesses that focus on this as their core competency. And finally, the demographics in lab automation are evolving into a much more diverse group. Ten to fifteen years ago, the lab automation community was a small cohort of scientists whom we thought of as tinkerers. Today, lab automation comprises scientists, engineers, software developers, IT professionals, and even executive leaders, who are interested in lab automation due to the significant investment and impact it will have on their scientific portfolios. Maria showed this slide earlier about the breadth of automation solutions, but I wanted to reiterate a few points. And we think about this as a journey. But really, it's a continuum. And we think about this as a crawl, walk, run, sprint journey to automation, moving from manual tasks to semi-automated tasks, leveraging instrumentation to thinking about how we transport materials from one place to another in the absence of humans? To being able to automate assays and experiments all the way to fully automated lights out biomanufacturing facilities integrated into the entire ecosystem of organizations, scientific portfolios, and the biosphere, has our Green Button Go software, where we're able to partner with laboratories to enable each one of these different phases. And we call it a continuum because the reality is laboratories are actually in various locations, part of their day-to-day operations. Even in the most fully automated labs, there are still aspects that have to be processed manually. And that's where the digitalization of those manual tasks becomes very important so that we can capture the data in a manual process in the same manner that data is being captured in a fully automated process. So what does lab automation entail? Well, when you hear about automation, you may think of large industrial robotic arms and conveyor belt systems. But in addition to the physical robots and instrumentation of lab automation, there are also the logical aspects. The logical aspects are comprised of the workflow, the business rules, the reagents, and the materials that will be used. But it also encompasses the interaction points between scientists and other humans as part of that overall process. And the third dimension to lab automation. And perhaps the most important, it's the data aspect, which is the reason we do science. And this is where Biosero was uniquely positioned with our offering. Not only do we have a hardware-agnostic software called Green Button Go, but we also have the ability to orchestrate the physical flow of materials throughout that workflow process while simultaneously orchestrating the digital flow of data. And by being hardware agnostic, it allows us to partner with scientists to integrate the latest and greatest technology or that particular scientist's favorite instrumentation as part of that overall process. And so, what does lab automation actually look like within the laboratory? I'm going to walk you through a common workflow that's done in laboratories all over the world to show you where we start when we think about how to automate the laboratory. In this case, you have a scientist who walks up to a storage unit. They are able to retrieve some dry compounds. They walk those dry compounds over to a balance at a bench, where they weigh out a certain amount of dry material into barcoded vials, capturing the weight of the material in those vials. They then take the dry material over to a pipetting station, where they'll add a certain volume of solvent to solubilize those samples at a desired concentration, and then they'll walk those solubilized vials over to a workstation, where the liquid handler will transfer a certain amount of those compounds into a compound plate. That compound plate is then walked over to another liquid handler, where it's met with a plate of cells that have been previously cultured on a cell culturing system. This liquid handler will dose the compounds onto the cells. It will add some reagents as part of the assay. And finally, the scientist will walk that assay plate over to some sort of analytical equipment where they'll conduct an endpoint analysis to achieve those experimental results. And so, although this shows the primary workflow that the sample would take in the laboratory. What's not being shown here are all the other manual touchpoints that are required to make this workflow possible. Scientists have to prepare buffer solution solvent blends. They need to reformulate reagents and building blocks to make them amenable for each one of these steps. New consumables are needed at each step along the way, and there's also waste and byproducts being generated that need to be discarded. So when you look at this workflow, you quickly realize there needs to be a way of managing or, better yet, orchestrating the laboratory. And so that's exactly what BICO does with our Green Button Go software; we not only orchestrate and control the instrumentation or the physical workflow of that experimental process. But we also orchestrate the digital flow of data. And when I talk about data, it's not only the upfront sample data and the endpoint experimental result, but also our ability to capture, contextualize, and harmonize all of the other data that's generated as part of this end-to-end workflow. And in the age of artificial intelligence and machine learning, it's this complete data package that is so vitally important to be able to train that AI and the machine learning algorithms, in order to allow laboratories to iterate and optimize their experimental processes. In addition to our Green Button Go software, Biosero has an industry-leading design and engineering team where we partner with scientists to bring their complete automated scientific vision to life from the ground up. In this video, you're seeing our engineering team leverage third-party and Beacon instrumentation to put this together into a fully automated platform that's automating the workflow that I just walked you through. That happens in many labs around the world in a manual process. And with that, I'm now going to turn it over to Derrick Miyao to give you a snapshot of AI-driven automated chemistry.

Derrick Miyao
69:38 - 82:28

Well, it's a pleasure to be here. Honor to be here. I came in from San Diego. It's not often that I get to experience this same weather, better weather than where I came from, but it's actually quite a pleasure to be here. With that being said, just to give you a bit of background on myself, I spent 20 years at One Biotech, a company in San Diego called Anakin Biosciences. I joined in 2017. For the first five years, we were really hot. We had a Phase III drug that got rejected, and we went through a bloodbath in 2007, and I was one of 58 to survive. But Neuron's valuation dropped to $100 million, and just a few weeks ago it hit $15 billion. I left two years ago when we saw a lot of success, mostly because I witnessed several significant changes. I saw the AI revolution really happening, and I wanted to be a part of it. And so I left New York. And so I left New York to join a startup to be a part of something special. So just to give you a bit of background on what I'm doing now, I've been at DeepCure for two years. It was founded out of the MIT Media Lab by Professor Schreiber, who was a student of Professor Joe Jacobson. Joe Jacobson's claim to fame includes several inventions, but notably he invented electronic ink, which is the tool used in the Kindle. Last week was our sixth birthday, and it was a big year. This is a big year for us because this is the year that we selected our first IND-enabling compound, where we're really taking it to human testing next year. But as you can see, we really believe in AI as well as possessing one of the world’s most advanced chemistry platforms. We have one of the world's most advanced chemistry platforms that Biosero has helped us build. Before I get into that though, I just want to discuss one of the problems with drug discovery, especially when it comes to small molecules. And this is what I did during the hurricane. And really, that downtime is what motivated me to make a significant difference in the chemistry segment. Chemistry is one of the last frontiers in science that has yet to be affected by modern technology. As you see, the way we did it 100 years ago is still being done the same way today. Not only is it slow, and not only are the chemists highly paid and highly educated, but as you see, the average burdened headcount in the US for a chemist is $350,000. In China and India, it's about $90,000, so it's significantly cheaper. But the biggest problem, though, was not the cost of the employees. It's the fact that the average chemist only synthesizes 1 to 2 compounds per week. And so if you actually think about the drug discovery process, it can take a team of 10 to 20 chemists up to two years just to get to that advanced lead status. It's really slow. Beyond the slowness and the cost, if we look at the image on the right, drug space is massive. We're talking 10 to the 60th power. And so when it comes to human history, we've made about 100 million molecules. It's barely a scratch on the surface. On top of that, this highly complex and manual science has been discussed in publications over the past 40 years. Most human chemists are only accessing 20 reactions. And the red shows a trend toward the blue, which represents modern times, indicating that we're performing more of the easier chemistry manually. Right. And that goes to human bias, where we do what we know we can do. And with each reaction type, there are more than a thousand reaction types. We're only using 20. And within each reaction type, you can perform it in more than a thousand ways. If we look at the middle category, there was an analysis done on all the small molecule drugs on the market. The average small molecule drug takes 4.8 steps of chemistry from start to finish. Your highly trained chemists, when they actually have to execute five steps of chemistry, succeed only 34% of the time. So we're talking like baseball. Like if you hit .340, you're going to be paid $20 million a year. Even in the first step of chemistry, which was with well-established processes, Johnson and Johnson did a study where their own chemists failed 20% of the time right out of the gate. Johnson and Johnson conducted a study where their chemists failed 20% of the time right out of the gate to further examine the issue. This is just a high-level example that DeepCure did. Where we look at the circle, these are the properties we believe are necessary to produce effective drugs. The purple or blue space in the middle represents billions of molecules that are virtualized by commercial companies selling compounds in small molecules. If you look at what's actually available, it's very limited and very confined to that red circle, to the red container around it, which is what I am evaluating. When I look at that space, there's nothing available to buy. So not only is it expensive and slow, but it's also limited in chemical space. And as a result, as you can see, we don't have very many effective drugs. So with this and the combination of expensive AI scientists, which is what DeepCure employs, that's when they brought me on and decided, hey, we want to change and revolutionize chemistry through automation. So this is just one small example of how Green Button Go and Biosero are really enabled. What we do in the lab. This is the purification process after synthesis. And what this does is it automates the analysis and purification of our synthesis. This obviously allows us to employ fewer chemists and enables us to focus on the AI algorithms. But more importantly, it significantly speeds up the science and the data processing. And so this process is typically done one at a time. And so you can imagine, well, we can buy multiple machines. Our biggest gain is running overnight and on the weekends. So if we look at where Green Button Go actually helps. Not only does it connect to our workflow from the start of the synthesis, but it also helps us understand what we did in the next process when it comes to the analytical analysis. From that analytical analysis, we've automated the purification verification aspect of it, where it selects the best conditions based on the feedback that it has received from Green Button Go instruments. And then, lastly, we can characterize it. We can weigh it, we can analyze it. And if we actually look at the tree of what Biosero actually touches, not only does it control the instruments as well as our workflow, but it controls all the instructions that go into our instruments. And sometimes there can be 10,000 instructions, and that's simply not possible for any human to perform. So Green Button Go really does enable the labs to do more with what we have. So this is how DeepCure's AI process is really laid out. We either design molecules using our AI algorithms or have human input. Once the molecules are selected, all the instructions are within our platform, and we use data from our platform to make these decisions, to create the instructions on how to make the molecules. Green Button Go then takes over from our internal software systems, and it manages the synthesis from start to finish. And from start to finish, it handles the synthesis, the purification, and the analysis, all the while communicating with our systems to say, 'Hey, this molecule didn't work.' Update the algorithm. This compound did work. Updated again. And we're constantly updating our algorithms and improving our chemistry at the same time. Most importantly, it's allowing us to create big data that helps our algorithms become usable. So if we look at some of the highlights and opportunities of creating systems like these, in my opinion the most valuable aspect that these systems will provide is when they are fully integrated into our systems, and the systems are fully controlled by our software, it’s going to create large and standardized chemical synthesis data that enables our predictive models. Keep in mind chemistry has been done by hand over the last hundred years. And when Maria said that 70% of papers aren't reproducible, for the first five years of my career, I actually thought I was a terrible scientist because I could only reproduce 30% of the papers. So if we think AI, if we can't do it as humans, what makes you think AI can do it? And so that's where I think the biggest opportunity lies in the fact that we're going to have data, especially when it comes to the chemistry that no one else has, that we can use with the AI algorithms. And more importantly, because we're not limited by bias, we will actually have a wide variety of negative data that will help us refine our models. The other important aspect is, and I've seen this in my own career, where automating chemistry creates faster turnaround times for those designs. Make, test, and analyze, especially when it comes to small molecules, because that has always been a bottleneck in the industry. Thus, the robotic platforms also generate standardized data, which enables us to develop AI and machine learning models. And beyond the drug discovery projects, there are a lot of different AI companies out there. We went to Google and asked them, 'Hey, do you want to do a drug discovery project with us?' And they said, no, we've done hundreds of those. But when we presented our chemistry data to them, we signed a partnership literally within a day because they had never seen data like that. Beyond the fact that humans typically conduct only 20 reactions, the simple reality that we can perform much more extensive chemistry means we're targeting hundreds of reaction types. This allows us to access the 'pink space' on the graph that no one else is accessing. And those hopes drive me; that we're going to make better drugs, hopefully cures instead of treatments. And then, lastly, the one thing that these systems do is that they don't allow for human bias because humans are not going to interact with the system. In fact, one thing I learned is that as long as I use my platforms to develop the chemistry using robotics, then I don't have to argue with a human to try different approaches. This machine will attempt as many processes as requested. And as such, we're going to get big data. So this is the result of this. And I know you financial analysts are going to love this slide. But we have one foundry that has two chemists. And what we can replicate when it comes to what I believe is the right amount of compounds to truly understand a biological receptor, which is about 300 molecules, and we're talking about complex molecules. We can do it for less than $10,000, which would traditionally cost about $1 million. We could do it much faster. And the speed is actually, in my opinion, more important than the cost, because we can move on to the next question. But what we can do can replicate 100 chemists, and we're just at the start of it. So taking all that information, DeepCure and my team, we wanted to show what this means and what that meant was we needed to do an example. So we took Paxlovid, which is a well-known molecule for COVID. It's a $20 billion molecule, I believe, or, sorry, the number four seller in 2022. It takes ten steps of chemistry to get there. And let me remind you that, as I said, when you have five steps, you get there 34% of the time. So to get to ten steps is even harder and less likely. We didn't just make one; we made it to demonstrate that we can create a single molecule, assign two chemists to it, and still genuinely innovate. We actually synthesized 56 analogs simultaneously, each requiring 9 to 10 steps. And the point of it was to show that instead of a process that's typically done one at a time, we did all at the same time. Analyzing all that data simultaneously is how you explore drug space and understand how chemicals interact with biological receptors. And that allows us to significantly accelerate the drug discovery process. We did publish this, and as such, if you want to look it up, it's in Genetic Engineering and Biotechnology News. And like I said, we're really just trying to disrupt the industry and truly change chemistry. And as a result of our platform, as a result of our capacity, as a result of where things are geopolitically, we think this is the right time to spin my group out and start its own company called Inspired Chemistry. And what we're trying to do is offer more chemicals in a wider chemical space so that we can get better molecules, and we're going to do it cheaper and faster. And with what you saw in the financial sheet, we can do it even cheaper than our Asian counterparts. And with that, I'll hand it back to Ryan Bernhardt.

Ryan Bernhardt
82:31 - 87:01

Thank you so much, Derek, for sharing that compelling story. So as you've just heard, Biosero has solutions that are able to meet the industry's greatest needs; we're able to partner with life science organizations to allow them to do more with less. For example, we can enable cost reduction while increasing their productivity and throughput. We can enable them in a global context to seamlessly transfer technology to different sites around the world. We can also enable the reproducibility of their validated scientific experiments. And in doing this, we're able to increase the quality not only of the science, but the quality of the data and the ability to track that data in a traceable format. And finally, we're enabling sustainable solutions where we can monitor progress, we can miniaturize experimentation, and we can minimize the waste that's being generated through lab automation. And so Biosero's growth strategy over the next five years can be broken down into five strategic levers. Number one, Biosero will continue to partner with life science organizations to enable end-to-end laboratory orchestration. Secondarily, Biosero will lead with software-centric solutions, where we'll work with instrument providers, DIY labs, and organizations. With the plan for the Green Button, we aim to become the Microsoft Windows model of lab automation. In addition to that, we'll continue to implement solutions that are closer to the patients and the end products in our ecosystem that are suitable for regulated laboratory environments. Fourth, we will enable scientific, workflow-centric solutions with instrument vendors, kit manufacturers, and even BICO sister companies like what you've heard with Sita's CE station being used for cell line development. And finally, we will generate recurring revenue by partnering with life science organizations to increase our value-added enhancements. This would include acting as a one-stop shop integrator for these large automation initiatives, as well as service contracts that embed Bio Team members in our organizational laboratories to ensure they're maximizing their return on investment. And then we're also launching Biosero's new online marketplace, which is essentially like an app store that provides convenience to laboratories to go in and exchange their software and add enhancements to their software package to ensure that their automation is able to evolve as their scientific portfolio evolves, or as their level of automation increases in the future. In this video, what you see is the culmination of Biosero's capabilities, coming together in partnership with a life science organization to enable a completely automated 'lights-out' biofactory that starts with incoming patient specimens. We're able to process those specimens into nucleic acid extraction, where we finally get results that give us genomic data that will now inform doctors and patients on the best path forward for their particular situation. We do this to accelerate research and development for life science organizations around the world through the use of software and integration capabilities. Ultimately, Biosero partners with life science organizations to enable them to accelerate scientific innovation to the market faster and more cost-effectively than ever before. and we collaborate with our sister companies at BICO AB to spin DeepCure's instruments, ensuring that their instruments are automation-ready and integration-friendly. Because we believe that advancing science that heals people, that feeds people, and that makes our lives better makes our world a better place to live is worth it. Thank you very much.

Anders Fogelberg
87:05 - 88:14

Thank you, Ryan. Thank you, Derrick, for this presentation. And we will have the opportunity to ask Ryan questions in the upcoming Q&A. And there will also be a demo session with lab automation for those who are here in Gothenburg. And, uh, Derek, thank you for showing us the lab of the future. What it looks like, that is already here now. And you've also warmed my heart when you complimented us on our famously beautiful customer. Whether it is now time for a break. Ten minutes sharp and then we will start the Q&A session. Welcome back to the final part of the Capital Markets Day. Our last topic on the agenda today is the Q&A, which will be moderated by Ulrik Trattner, equity analyst at Carnegie. And as I said before, those of you who are online, you can post your questions at any time by clicking on the chat box below the presentation. And for those of you who are here in the room, please raise your hand and you will be handed a microphone. Please speak into the microphone so that everyone attending online can hear your question. And with that, I hand it over to you.

Ulrik Trattner
88:15 - 89:12

Thank you very much, Anders. And thank you very much, Michael, for allowing me to host this Q&A session and potentially also for those of you in the room who would like to ask a question. Please state your name and the firm you're representing. So that is clear for everyone in the audience. Uh, but since I'm in control of the microphone, I'll start off with a few questions. And given that we have the pleasure to have you here, Ryan, representing Biosero. So I think we'll start off there. Um, you were joined by Co and O0 and you came from leading lab automation at Eli Lilly. Uh, so the first question would be on the industry side, on the other side, on the customer side: you’re experienced in lab automation, where are we at today? Um, and if there are any hurdles on the customer side in adopting an automated workflow.

Ryan Bernhardt
89:13 - 91:08

Thank you for the question again. It's a pleasure to be here. Um, I think, you know, I had the privilege of being on both sides of the aisle, from being a technology provider to also being a user and customer of automation in order to do science during my time at Lilly and also elsewhere in my career journey. One of the greatest mechanisms to accelerate scientific research is through being able to extend the hours of productivity and do more with less. And that was exactly the challenge we faced during my time at Lilly. I'm proud of the fact that we were very much pioneers in enabling automation and actually making some very bold, large investments in automation. One of the first to automate the design, make, test, analyze cycle. That really broke down some of those internal historical silos of different technologies and groups coming together to accelerate that. I think some of the biggest challenges we face today in the laboratory is access to the data. It's that data that is needed to make better decisions. And having not only access to the full data, but also having it quickly so we can advance our goals. And so that's a big aspect of what we're enabling at Biosero; we have a concept of no data left behind, and it's through the ability to control the instruments and orchestrate the workflow that we then have access to that data. And being able to make that data available. Back to the organization to continue down the project portfolio is a big aspect, and it's one of the biggest challenges that the industry faces.

Ulrik Trattner
91:09 - 91:32

And could you talk a little bit about how in your experience, both on the customer side as well as on the Biosero side, how customers adopt lab automated software or workflow? Do they go lab by lab or do they go by a therapeutic area? By therapeutic area? Um, just to get a sense of how it's implemented.

Ryan Bernhardt
91:32 - 92:50

Great question. You know, we often say, one of our best sales reps is a happy customer. And this is true in the world of lab automation. It's actually a very small community. Most organizations have automation focal points or groups within the organization that partner with scientists and stakeholders to help implement automation for their particular science. It's those focus groups or cohorts within that company that typically move from one lab or one area of the business to then automating, helping another area automate. So, for example, if an oncology group brings in lab automation for the first time and it's a bio-enabled system, when they have a good experience there and successfully implement it, that same group will likely go on to endocrinology, neuroscience, and other therapeutic areas where they can apply those learnings and success stories to further implementations. So there's definitely kind of a spiderweb-like approach to the way it's implemented within many organizations. Not all are set up like that, but a very many are.

Ulrik Trattner
92:51 - 93:08

And do you dare to give a guesstimate on the sort of percentage of penetration? And if we were to single out big Pharma, otherwise the space would get potentially too wide. Where do you think we are today, and where do you think we will be in the next five years?

Ryan Bernhardt
93:09 - 94:06

So although the industry is greatly evolving and there's a very high demand, I believe we've only scratched the surface for the potential of lab automation in pharma, biotech, agricultural science, and diagnostics as well. So I think we're in very, very early stages, and I definitely think that this is a necessity as we move forward. You know, one of the things that also happens in academia is that we still have many scientific students learning the traditional ways. It's not until they enter the industry that they may, for the first time, encounter the use of automation technology to do science. And I think that there's a real potential there to get automation and sophisticated instrumentation earlier as part of that learning or training, which will also help to further catalyze this.

Maria Forss
94:06 - 94:59

And to add to that, maybe we can have slide 31 and just reiterate the data on this emerging market. And as I said in my presentation, in this infant industry, there are a lot of different reports floating around. And those reports show that the market value ranged between 5.5 and 6.8 billion USD last year, with a growth rate of between 6.3% and 9.3% from 2023 to 2035. And out of this, Biosero is addressing a market with the orchestrated solutions that Ryan presented earlier, which we estimate to be 20% of that overall market. And with the growth we observe, it is estimated to outpace the overall lab automation market.

Ulrik Trattner
95:02 - 95:12

And, feel free to ask questions. Don't be shy. I assure you that it will be harmless. We have a question here from Ricardo.

Unknown 1
95:17 - 96:01

Thank you for taking my questions. Perfect. Thank you for taking my questions. Regarding recurrent accounts from Handelsbanken. Uh, starting off with margins of Biosero. Margins were a little bit lower in 2022 and 2023 compared to the time of acquisition, as the company has grown quite significantly. Maybe you could talk a little bit about the margin development, explaining the changes and also discuss the scalability in that business. How we should see rapid growth versus rising margins, etc., in the business just to get a sense of how it scales as you grow. Because there's quite a bit of consultancy or implementation from a manual side as well.

Jacob Thordenberg
96:01 - 96:44

Thank you. Sure. It's a very good question. And as we saw, we had significant growth from 2022 to 2023. However, that had an impact on margins. But on the other hand, we grew by 40%. And in retrospect, maybe we grew a little bit too fast in 2023 because we had lots of demand from the market that we wanted to meet. Going into 2024, we are much more selective in the projects we accept and decide to pursue. And we are also adding lots of resources in Biosero when it comes to operational planning and how we sort of structure ourselves in order to be able to scale Biosero, keeping high margins.

Unknown 1
96:46 - 97:14

And maybe just a quick follow-up if I can. You know, how should we think about the larger deals you announced last year? You know, the $28 million order? I guess you will be looking to get additional orders of magnitude in the coming years. Um, how should we think about the margin profile of larger deals, or are they pushing Biosero's profitability as the deals grow larger? Or maybe you can help explain the dynamics of the size of the deals.

Jacob Thordenberg
97:14 - 97:27

Sure, I can do that. But I won't go into too much specifics or discuss the margins of larger deals. Uh, but the larger deals are in line with the overall margin of Biosero.

Ulrik Trattner
97:29 - 97:52

Thank you. Great. And can we talk about the competitive profile of Biosero? Um, you're up against solutions from TXN, Thermo Fisher, Hamilton, Beckman Coulter. Um, what is sort of the key aspect? Why do the customers end up going to Biosero? And what would you regard the barrier of entry as being?

Ryan Bernhardt
97:53 - 100:23

Great question. So, Biosero was uniquely positioned in that we have a scheduling software typically used to control instrumentation and processes at the integrated work cell level. But we also have an orchestration software that actually goes beyond any single integrated work. So you can think of this as the orchestration of an entire laboratory where it controls multiple work cells, the ability to integrate standalone instruments in the lab, and also the transportation of materials, as well as the capture and harmonization of that data. That is a very unique position to be in for Biosero on the market, as we're one of the only ones that have both of those aspects. The other aspect that we have is that we are hardware agnostic, and that is a unique position to be in. Also, many of the other providers of integrated automation are actually hardware-centric in nature. So, meaning they started with a hardware component, either a liquid handler or a high-content imager. And then out of that, they tried to build an integrated software solution. But at the foundation, the software solution was originally made to pipette volume from one vessel to another on an automated liquid handler. We've approached this from a unique perspective, where it's a software-centric solution that focuses on automating processes rather than the hardware. This allows us to leverage the latest and greatest technology available, or a customer’s favorite hardware. And it puts us in a unique position as well, where we see most instrument vendors as partners, and we work together to enable their instrumentation to be used in an automated setting. So I think that's a very unique value proposition that Biosero is in. We also have a great deal of experience from consulting, on the consulting side of the business. Anywhere there's a laboratory doing research and development, Biosero is applicable. And this means that we span a lot of different markets and a lot of different scientific applications. And we can bring all of that experience and knowledge, being able to partner with customers whether they're in an agro science laboratory or a pharmaceutical laboratory, and different therapeutic areas as well.

Maria Forss
100:25 - 100:39

I think some might wonder about, well, this software, how sticky is it? But you're talking about the experience, right? I think it would be helpful also for the audience as well as the viewers online, if you just speak a bit about the over 400 drivers and how they come into play.

Unknown 2
100:39 - 100:40

Sure, I can do that.

Ryan Bernhardt
100:40 - 101:44

Very good point. So, one of the aspects that we consider the crown jewels of scheduling software is the device or instrument drivers. This is essentially the piece of code that allows us to control and communicate with different scientific instruments. Biosero today has over 400 instrument drivers that we've spent many, many years developing, working alongside customers, working alongside instrument providers to develop and iterate upon these, ensuring that we have robust, reliable communication and air handling capabilities, which really becomes a key foundation of any good scheduling or orchestration software today. On the orchestration side, we're also doing something similar as it comes to connecting and integrating with informatics and software packages such as LIMS systems, airlines, and inventory management systems. Um, as we look to move and connect data from system to system.

Ulrik Trattner
101:46 - 102:11

And you mentioned, it's hardware agnostic. And then I would turn to you, Maria, with the rest of the portfolio system that you beautifully showcased here. How are you? What are you doing to drive synergies and leverage the biosphere platform with the rest of your portfolio? And where should we expect to see the synergies?

Maria Forss
102:12 - 104:53

I believe Ryan touched upon part of this very relevant question in his presentation. With such good relationships and customer insights, working with all the top pharmaceutical players in the life sciences world, that means that the team at Biosero gets a lot of our customer insights, which we can deploy to also the other companies within the group. So hence we know what needs we need to serve. And, um, when it comes to addressing this, I think maybe we should show. Slide 43. Just to reiterate, how everything connects. So I mean, in essence, we have lab automation, but also selected workflows. And as we have decided to work with six selected workflows, we address the different needs through our customers to ensure that for cell line development, next-generation sequencing, we can then make sure that we have the three different levels, either fully customized automated solutions by Biosero or I believe that many of your customers are asking for products from Selena, from Santana, from Bendix, etc., as part of the fully automated workflows. But these products can take a year or sometimes two. Um, since there is such a need for automated workflows, we can also identify more standardized workflows. And then we have products such as RC Station from Katina, where it's more of an off-the-shelf workflow utilizing the insights and having something which we can then deliver in six months, and also to connect instruments and consumables. We also have standard operating procedures such as the G prep from the Spanx, or then facilitate the next generation sequencing part by having a protocol that our customers can follow from A to Z. So that's another way of automating. So, from joining and having a group of companies that were like isolated islands. We have a group now with 12 companies that communicate with each other, all knowledgeable and having participated in the development of this strategy. So we have identified which touchpoints exist and the collaboration opportunities available to us, ensuring that we address comprehensive solutions rather than just point solutions. We address this in holistic end-to-end workflows and then utilize the fact that we are a larger group, not just 12 individual companies. Jakob, do you want to add anything?

Jacob Thordenberg
104:53 - 105:06

I think it's fairly summarized on slide 45. And I think, as you say, Maria, it's the selected workflows in combination with the fact that we can integrate these selected workflows with the green button software, which our competitors cannot.

Ryan Bernhardt
105:06 - 106:01

And if I may add, we are also collaborating with our sister companies to ensure that they are designing their instrumentation with robust APIs for digital communication, as well as automation-friendly access for robotic arms and mobile robots. And then the China Station is a great example of a collaboration that was between Biosero and Katina, where it was originally Biosero's integration and engineering team that worked alongside Katina to take their workflow and design what would become a standard solution that then would be part of the China portfolio. But it was through a collaboration that began with the design, the engineering services, and ultimately by powering that solution. But because it's a standardized offering, it's now part of the science portfolio.

Maria Forss
106:01 - 106:15

And as I mentioned when talking about the standard operating procedure. Sometimes we also partner with other companies to provide holistic end-to-end workflows. And maybe in a couple of words, what we do together with Sartorius and Biosero.

Ryan Bernhardt
106:16 - 107:03

Yeah. So we're working with Sartorius on a similar thing to what we've done with other sister companies, and that is to ensure that we have automation solutions for several of their instruments and devices. We also develop automation solutions in coordination with them that are, again, on a smaller scale, which we call a reader feeder. It's essentially a robotic arm that allows interaction with multiple plates. But then we also look at how we can integrate those instruments into a much larger end-to-end workflow process. And we're working together as SLAs approach, which is the big conference for lab automation. We'll be showcasing some of that work together with Sartorius and other organizations at that conference in January.

Ulrik Trattner
107:05 - 107:34

And is that something that is part of your strategic agenda going forward? I know you touched upon it throughout the presentation to explore and elaborate more on partnerships, so how should we view this going forward? Should we see that as you collaborating on certain projects, or would you be willing to go more on a distributed route via these companies, or what is the best way going forward?

Maria Forss
107:34 - 109:05

I think there are many different levels to that. That question. And, I mean, you can identify in these six addressed workflows where we have the majority of our portfolio covered. Some of these workflows have gaps, and then we can choose to either develop something on our own in R&D, or we can partner with someone that has a reagent, consumable, or an instrument that fills that gap. So, I think it needs to be on an individual basis to see what is suited for that purpose and to determine if it is best to collaborate with someone? Is it better to innovate yourself or acquire something? So, in terms of partnerships, that is what our Chief Commercial Officer, Anders Fogelberg, is responsible for. And he is also the main responsible person for our Sartorius collaboration, where we, apart from what Ryan described, also have other development projects primarily within organoids, bioprinting, as well as digitalization. So, apart from the Biosero ones, we also have collaboration in terms of 3D models with our tissue model company Matic, and also a 3D printing project for biopharma. So, the recently launched initiatives that we are conducting together with Sartorius focus particularly on digital applications and lab automation, which are aligning with the BICO strategy 2.0.

Ulrik Trattner
109:07 - 109:23

And from the web, I received several questions regarding the convertible debt. So if we can switch focus on that. Your strategic plan on how to refine this is due on March 26th, as you mentioned. Well, the plan first off, as I mentioned, I mean, the current solution serves us very well and the bond is not due until March 2026, but we are looking into various options on how to refinance the bond.

Jacob Thordenberg
109:24 - 109:59

Well, the plan first off, as I mentioned, I mean the current solution serves us very well and the bond is not due until March 2026, but we are looking into various options on how to refinance the bond. One of the options, and so the main target, is of course that we continue to conduct operational excellence activities. We focus on our strategic priorities. We will execute on the updated strategy. But in addition to that, we are also exploring different options, including the strategic fit of our assets in the portfolio.

Ulrik Trattner
110:01 - 110:10

And would you be willing? Should we interpret that as your willingness? To sell off certain assets in order to refinance.

Jacob Thordenberg
110:10 - 110:22

Interpret it as us doing everything we can to maximize shareholder value. And as a part of that, we're also, of course, exploring the value of our portfolio of assets.

Unknown 3
110:24 - 110:24

Great.

Ulrik Trattner
110:24 - 111:01

And I see that you have not changed your financial targets. Um, as you mentioned, they are below your financial targets. It is a challenging environment. Lower CapEx for pharma and some hurdles on the public financing healthcare side. Um, how should we view the financial targets in the short term as well as in the medium term? And I also note that you didn't change your net debt to EBITDA target, which then would imply that we should see operational leverage until the financing and refinancing of the convertible.

Unknown 4
111:01 - 111:02

Well, it.

Jacob Thordenberg
111:02 - 111:29

Depends on how you see it, because we also have cash levers, as I'm alluding to in our portfolio of assets. So that's also, of course, a solution. But the target should be viewed as a mid-term objective. As we have said many times now, we are indeed operating in a tough market. We do see capital restraints and CapEx holdbacks. So, in the near term, we do see a quite tough market, or have seen a tough market.

Ulrik Trattner
111:31 - 111:55

One of your focus points in this presentation is to concentrate efforts on streamlining the organization to enhance business operations and increase shareholder value. And one point is, obviously, R&D in your organization. So how should we view R&D spending going forward? And would you say that your current operations are future-proof?

Maria Forss
111:58 - 111:58

Should I?

Unknown 5
112:00 - 112:00

Um.

Maria Forss
112:00 - 114:06

I think it's fair, given that we have spent or invested quite a substantial part of our turnover in R&D in the past years. Uh, from 22% three years ago, 16% two years ago, and 12% last year, I believe. And, uh, I think one shouldn't see it as the amount spent. We have a fantastic portfolio, given those investments. But what is important moving forward is that we focus on the right investments. I also mentioned that in terms of our achievements, we have conducted a comprehensive review of our R&D portfolio and product offerings. I also mentioned briefly that we are not fully ready yet, and the reason for that is we conducted this review last spring. We were finished in May, and by that time, our new and updated strategy wasn't in place. So it's impossible to steer new R&D investments before we have an updated strategy in place. So now, with new eyes and glasses, our operational companies are reviewing their R&D pipelines moving forward, and what we invest in moving forward should be focused and also drive towards the new updated strategy. And we will do that based on customer insight. And we will have a customer-centric R&D, which should also follow a stage-gate process to ensure that we fulfill the business cases that we should have. And when I say focused, it means choosing what to do and also what not to do. And I'd rather have, and I'm making this fictitious number up now. I'd rather have four projects that go full steam ahead, than having eight that are on half speed and then take twice the time. So that's what we mean by focus. And the optimization will come after we implement the updated strategy towards our R&D pipeline.

Ulrik Trattner
114:07 - 114:18

Great. Unfortunately, the Q&A time is up. Um, again, thank you, Michael, for allowing me to host this Q&A, and I'll hand over the word to you on it.

Anders Fogelberg
114:18 - 114:36

Thank you. Thank you, Ulrik, for moderating this Q&A. And this leads to the end of today's online Capital Markets Day. But before we finalize, let's have a few final words by Maria. Thank you, Eric.

Maria Forss
114:37 - 116:12

Thank you for joining us today, both here in Gothenburg as well as online. We appreciate your time and also your attention as we unveiled our updated strategy and shared our in-depth look at how lab automation and holistic workflow offerings should be made in the future for BICO AB. I also want to take the opportunity to thank all talented BICO employees around the world for their dedication, as well as express my gratitude to our customers and business partners who continuously put their trust in BICO, especially appreciated in the tough market we're in, when capital is more scarce and R&D investments often are on hold. As we move forward, our commitment remains steadfast in creating sustainable, profitable growth and maximizing shareholder value. This will not be a quick fix. There's still much work to do as we continue to work diligently to become the first choice lab automation partner and provider of selected workflows to pharma and biotech. And your continued support and trust in our vision is important, especially in this tough market, as we embark on the next chapter on the BICO journey starting today, where we will enable and automate the lab of the future. And now the true work begins. And by that, I will hand over to Anders for some final words.

Anders Fogelberg
116:12 - 116:45

Thank you, Maria. The presentation deck that you saw today is already available on our website at bico.com, and the live sessions from today will also be posted on our website as of tomorrow. It will be an on-demand version. You can register and gain access. And with that being said, I thank everyone who has been joining us online and everyone here in Gothenburg. And with that, we finalized the first part of today's Capital Markets Day. Thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…